CRISPR-edited MuSCs from dystrophic mice, when engrafted in a dystrophin null mouse, showed increased dystrophin expression and successful renewal.75,76 These studies taken together demonstrate that with further development, in vivo gene editing approaches will be clinically useful for treating DMD. Here, DMD is linked to Duchenne muscular dystrophy.